IMMUNOTHERAPEUTIC COMPOSITION FOR THE TREATMENT OF CANCER

Yoram Reiter; Netta Haim

IMMUNOTHERAPEUTIC COMPOSITION FOR THE TREATMENT OF CANCER

Yoram Reiter (Inventor), Netta Haim (Inventor)

Biology

Technion - Israel Institute of Technology

Research output: Patent

Abstract

The present invention provides compositions and methods for inducing allogenic tumor rejection and, more particularly, but not exclusively, compositions and methods employing fusion proteins comprising an MHC class I HLA amino acid sequence mismatched to the host.

Original language	American English
Patent number	US2020385441
IPC	C07K 16/ 30 A I
Priority date	20/08/20
State	Published - 10 Dec 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Cite this

@misc{13271771f5f9455da8fa75c7552a76e7,

title = "IMMUNOTHERAPEUTIC COMPOSITION FOR THE TREATMENT OF CANCER",

abstract = "The present invention provides compositions and methods for inducing allogenic tumor rejection and, more particularly, but not exclusively, compositions and methods employing fusion proteins comprising an MHC class I HLA amino acid sequence mismatched to the host.",

author = "Yoram Reiter and Netta Haim",

year = "2020",

month = dec,

day = "10",

language = "American English",

type = "Patent",

note = "US2020385441; C07K 16/ 30 A I",

}

TY - PAT

T1 - IMMUNOTHERAPEUTIC COMPOSITION FOR THE TREATMENT OF CANCER

AU - Reiter, Yoram

AU - Haim, Netta

PY - 2020/12/10

Y1 - 2020/12/10

N2 - The present invention provides compositions and methods for inducing allogenic tumor rejection and, more particularly, but not exclusively, compositions and methods employing fusion proteins comprising an MHC class I HLA amino acid sequence mismatched to the host.

AB - The present invention provides compositions and methods for inducing allogenic tumor rejection and, more particularly, but not exclusively, compositions and methods employing fusion proteins comprising an MHC class I HLA amino acid sequence mismatched to the host.

M3 - Patent

M1 - US2020385441

ER -